Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers

• Published in: Clinical pharmacokinetics Vol. 53; no. 10; pp. 931 - 941
• Main Authors: Brill, Margreke J. E., van Rongen, Anne, Houwink, Aletta P. I., Burggraaf, Jacobus, van Ramshorst, Bert, Wiezer, René J., van Dongen, Eric P. A., Knibbe, Catherijne A. J.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.10.2014; Adis International; Springer Nature B.V
• Subjects: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Biological and medical sciences; Biological Availability; Case-Control Studies; Female; General pharmacology; Healthy Volunteers; Humans; Hypnotics and Sedatives - administration & dosage; Hypnotics and Sedatives - blood; Hypnotics and Sedatives - pharmacokinetics; Internal Medicine; Male; Medical sciences; Medicine; Medicine & Public Health; Metabolic diseases; Midazolam - administration & dosage; Midazolam - blood; Midazolam - pharmacokinetics; Middle Aged; Models, Biological; Obesity; Obesity, Morbid - blood; Obesity, Morbid - metabolism; Original; Original Research Article; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions; Pharmacology. Drug treatments; Pharmacology/Toxicology; Pharmacotherapy; Prospective Studies; Time Factors; Young Adult; Morbid Obesity; Ultra Performance Liquid Chromatography; Obese Patient; Midazolam; Oral Bioavailability; Human; Obesity; Intravenous administration; Healthy subject; Psychotropic; Nutrition disorder; Oral administration; Hypnotic; Benzodiazepine derivatives; Sedative; Pharmacokinetics; Nutritional status; Comparative study
• ISSN: 0312-5963; 1179-1926; 1179-1926
• DOI: 10.1007/s40262-014-0166-x

Background While in vitro and animal studies have shown reduced cytochrome P450 (CYP) 3A activity due to obesity, clinical studies in (morbidly) obese patients are scarce. As CYP3A activity may influence both clearance and oral bioavailability in a distinct manner, in this study the pharmacokinetics of the CYP3A substrate midazolam were evaluated after semi-simultaneous oral and intravenous administration in morbidly obese patients, and compared with healthy volunteers. Methods Twenty morbidly obese patients [mean body weight 144 kg (range 112–186 kg) and mean body mass index 47 kg/m 2 (range 40–68 kg/m 2 )] participated in the study. All patients received a midazolam 7.5 mg oral and 5 mg intravenous dose (separated by 159 ± 67 min) and per patient 22 samples over 11 h were collected. Data from 12 healthy volunteers were available for a population pharmacokinetic analysis using NONMEM ® . Results In the three-compartment model in which oral absorption was characterized by a transit absorption model, population mean clearance (relative standard error %) was similar [0.36 (4 %) L/min], while oral bioavailability was 60 % (13 %) in morbidly obese patients versus 28 % (7 %) in healthy volunteers ( P  < 0.001). Central and peripheral volumes of distribution increased substantially with body weight (both P  < 0.001) and absorption rate (transit rate constant) was lower in morbidly obese patients [0.057 (5 %) vs. 0.130 (14 %) min –1 , P  < 0.001]. Conclusions In morbidly obese patients, systemic clearance of midazolam is unchanged, while oral bioavailability is increased. Given the large increase in volumes of distribution, dose adaptations for intravenous midazolam should be considered. Further research should elucidate the exact physiological changes at intestinal and hepatic level contributing to these findings.